611 related articles for article (PubMed ID: 22266473)
1. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
[TBL] [Abstract][Full Text] [Related]
2. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.
Sanoff HK; Carpenter WR; Stürmer T; Goldberg RM; Martin CF; Fine JP; McCleary NJ; Meyerhardt JA; Niland J; Kahn KL; Schymura MJ; Schrag D
J Clin Oncol; 2012 Jul; 30(21):2624-34. PubMed ID: 22665536
[TBL] [Abstract][Full Text] [Related]
3. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.
Sanoff HK; Carpenter WR; Freburger J; Li L; Chen K; Zullig LL; Goldberg RM; Schymura MJ; Schrag D
Cancer; 2012 Sep; 118(17):4309-20. PubMed ID: 22294436
[TBL] [Abstract][Full Text] [Related]
4. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
Panchal JM; Lairson DR; Chan W; Du XL
Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
[TBL] [Abstract][Full Text] [Related]
5. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Yothers G; Sargent DJ; Wolmark N; Goldberg RM; O'Connell MJ; Benedetti JK; Saltz LB; Dignam JJ; Blackstock AW;
J Natl Cancer Inst; 2011 Oct; 103(20):1498-506. PubMed ID: 21997132
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy.
Lund JL; Sturmer T; Sanoff HK
J Geriatr Oncol; 2016 May; 7(3):176-86. PubMed ID: 26926829
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
Hsiao FY; Mullins CD; Onukwugha E; Pandya N; Hanna N
J Am Geriatr Soc; 2011 Sep; 59(9):1717-23. PubMed ID: 21831168
[TBL] [Abstract][Full Text] [Related]
8. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
10. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
André T; Meyerhardt J; Iveson T; Sobrero A; Yoshino T; Souglakos I; Grothey A; Niedzwiecki D; Saunders M; Labianca R; Yamanaka T; Boukovinas I; Vernerey D; Meyers J; Harkin A; Torri V; Oki E; Georgoulias V; Taieb J; Shields A; Shi Q
Lancet Oncol; 2020 Dec; 21(12):1620-1629. PubMed ID: 33271092
[TBL] [Abstract][Full Text] [Related]
11. Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy.
Mack CD; Glynn RJ; Brookhart MA; Carpenter WR; Meyer AM; Sandler RS; Stürmer T
Pharmacoepidemiol Drug Saf; 2013 Aug; 22(8):810-8. PubMed ID: 23296544
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.
Iwashyna TJ; Lamont EB
J Clin Oncol; 2002 Oct; 20(19):3992-8. PubMed ID: 12351596
[TBL] [Abstract][Full Text] [Related]
13. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.
Shah MA; Renfro LA; Allegra CJ; André T; de Gramont A; Schmoll HJ; Haller DG; Alberts SR; Yothers G; Sargent DJ
J Clin Oncol; 2016 Mar; 34(8):843-53. PubMed ID: 26811529
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Haller DG; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Gilberg F; Rittweger K; Schmoll HJ
J Clin Oncol; 2011 Apr; 29(11):1465-71. PubMed ID: 21383294
[TBL] [Abstract][Full Text] [Related]
15. Effect of adjuvant chemotherapy on survival benefit in stage III colon cancer patients stratified by age: a Japanese real-world cohort study.
Kawamura H; Morishima T; Sato A; Honda M; Miyashiro I
BMC Cancer; 2020 Jan; 20(1):19. PubMed ID: 31906959
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
17. The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.
Cheung WY; Shi Q; O'Connell M; Cassidy J; Blanke CD; Kerr DJ; Meyers J; Van Cutsem E; Alberts SR; Yothers G; Sargent DJ;
Clin Colorectal Cancer; 2013 Sep; 12(3):179-87. PubMed ID: 23810482
[TBL] [Abstract][Full Text] [Related]
18. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Grothey A; Sobrero AF; Shields AF; Yoshino T; Paul J; Taieb J; Souglakos J; Shi Q; Kerr R; Labianca R; Meyerhardt JA; Vernerey D; Yamanaka T; Boukovinas I; Meyers JP; Renfro LA; Niedzwiecki D; Watanabe T; Torri V; Saunders M; Sargent DJ; Andre T; Iveson T
N Engl J Med; 2018 Mar; 378(13):1177-1188. PubMed ID: 29590544
[TBL] [Abstract][Full Text] [Related]
19. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.
Zuckerman IH; Rapp T; Onukwugha E; Davidoff A; Choti MA; Gardner J; Seal B; Mullins CD
J Am Geriatr Soc; 2009 Aug; 57(8):1403-10. PubMed ID: 19563521
[TBL] [Abstract][Full Text] [Related]
20. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
Mack CD; Carpenter W; Meyer AM; Sanoff H; Stürmer T
Cancer; 2012 Jun; 118(11):2925-34. PubMed ID: 22072441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
